Global Angina Market Growth Accelerates: Strategic Forecast Predicts $14.18 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Angina Industry Market Size Be by 2025?
The market associated with angina has experienced robust expansion over the past few years, projected to increase from a value of $10.71 billion in 2024 to $11.36 billion a year later, reflecting a compounded annual growth rate (CAGR) of 6.1%. This upward trajectory observed historically stems from several factors, including a higher incidence of coronary heart disease, greater prescription rates for vasodilators, escalating occurrences of myocardial ischemia, advancements in diagnostic tools, and the wider application of various imaging methodologies.

What's the Long-Term Growth Forecast for the Angina Market Size Through 2029?
Forecasting robust expansion, the angina sector is projected to achieve a valuation of $14.18 billion by 2029, driven by a consistent compound annual growth rate (CAGR) of 5.7%; this anticipated upward trajectory is fueled by several factors, notably the rising incidence of chronic angina pectoris, an uptick in both drug approvals and associated clinical investigation, a growing reliance on retail pharmacy channels, heightened public consciousness regarding cardiovascular wellness, and an escalating need for therapeutic interventions. Key developments shaping this market during the forecast timeframe encompass progress in early diagnostic technologies, improvements in angioplasty procedures and stent technology, the emergence of novel gene therapy methodologies, significant demand for coronary stents, and continuous evolution in treating coronary artery disease.

View the full report here:
https://www.thebusinessresearchcompany.com/report/angina-global-market-report

What Are the Key Growth Drivers Fueling the Angina Market Expansion?
Anticipated escalation in the incidence of coronary artery disease is projected to fuel the expansion of the angina market moving ahead. Coronary artery disease (CAD), which is interchangeably referenced as coronary heart disease (CHD) or ischemic heart disease (IHD), describes a state where the arteries responsible for delivering blood, oxygen, and nourishment to the cardiac muscle become constricted or obstructed. This increasing frequency of CAD is attributable to evolving lifestyle patterns alongside environmental and inherited predispositions, and the manifestation of angina is instrumental in both recognizing and grasping the broad occurrence of coronary artery disease, necessitating medical scrutiny and diagnosis, aiding in risk categorization, shaping therapeutic choices, and influencing overall public health planning; as an illustration, data from the American Heart Association indicated that between 2021 and 2022, the population of U.S. adults affected by CAD increased from 18.2 million to roughly 19.3 million as of January 2023, consequently, the escalating prevalence of coronary artery diseases acts as a catalyst for the angina market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16337&type=smp

What Are the Key Trends Driving Angina Market Growth?
Prominent entities engaged in the angina therapeutic sector are actively formulating novel pharmaceutical agents, such as metoprolol tartrate tablets, aiming to deliver superior and more focused interventions for individuals afflicted by coronary artery disease and associated ailments. Metoprolol tartrate tablets represent a widely utilized medication class employed in addressing a spectrum of cardiac issues, encompassing angina (discomforting chest sensations), elevated blood pressure (hypertension), and cardiac insufficiency. Illustratively, in April of 2023, the Indian pharmaceutical firm Zydus secured definitive authorization from the US-FDA to proceed with the production and commercialization of its bioequivalent Metoprolol Tartrate Tablets USP, available in dosages of 25 mg, 50 mg, and 100 mg. This compound, metoprolol, functions as a beta-blocker, prescribed for managing diverse heart and circulatory problems like hypertension and angina, while also enhancing post-myocardial infarction survival rates.

How Is the Angina Market Segmented?
The anginamarket covered in this report is segmented -

1) By Type: Angina Pectoris; Unstable Angina; Prinzmetal Angina; Other Types
2) By Treatment: Lifestyle Changes; Medications; Angioplasty And Stenting; Coronary Bypass Surgery; Other Treatments
3) By Drug Class: Beta Blockers; Nitrates And Calcium Channel Blockers; Angiotensin-Converting Enzyme Inhibitors; Other Drug Classes
4) By Application: Clinics; Hospitals; Other Applications

Subsegments:
1) By Angina Pectoris: Stable Angina; Chronic Stable Angina; Effort-Induced Angina; Variant Or Microvascular Angina
2) By Unstable Angina: Acute Unstable Angina; Pre-Infarction Angina; Rest Angina
3) By Prinzmetal Angina: Vasospastic Angina; Coronary Artery Spasm-Induced Angina; Variant Angina
4) By Other Types: Nocturnal Angina; Post-Infarction Angina; Angina With Silent Myocardial Ischemia; Angina Due To Aortic Stenosis Or Valve Disease

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=16337&type=smp

Which Companies Are Leading the Charge in Angina Market Innovation?
Major companies operating in the angina market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co Inc., Bayer AG, Sanofi S.A., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott laboratories, GlaxoSmithKline Plc, Eli Lilly and Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Troikaa Pharmaceuticals Ltd, Amgen Inc., Dr. Reddy's Laboratories, ViroMed Co. Ltd., Lee's Pharmaceutical Holdings, Kuhnil Pharmaceutical, LegoChem Biosciences, Axus Cardium Pharmaceuticals, Juventas Therapeutics, Milestone Pharmaceuticals

Which Regions Are Leading the Global Angina Market in Revenue?
North America was the largest region in the angina market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16337

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.